,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-11-18 07:00:00,The following are the top rated Healthcare stocks according to Validea's Contrarian Investor model based on the published strategy of David Dreman .,0.033474262803792953,0.005644673015922308,0.9608810544013977,neutral,0.027829589322209358
1,2018-11-18 07:00:00,This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.,0.1901920884847641,0.4970625638961792,0.3127453625202179,negative,-0.3068704605102539
2,2018-11-18 07:00:00,SENIOR HOUSING PROPERTIES TRUST ( SNH ) is a mid-cap value stock in the Healthcare Facilities industry.,0.06708278506994247,0.005497176665812731,0.9274200201034546,neutral,0.06158560886979103
3,2018-11-18 07:00:00,The rating according to our strategy based on David Dreman is 70% based on the firm's underlying fundamentals and the stock's valuation.,0.0312923938035965,0.005273972172290087,0.9634336233139038,neutral,0.026018422096967697
4,2018-11-18 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
5,2018-11-18 07:00:00,Company Description: Senior Housing Properties Trust is a real estate investment trust (REIT).,0.016861308366060257,0.006089508533477783,0.9770491719245911,neutral,0.010771799832582474
6,2018-11-18 07:00:00,"The Company's segments include triple net senior living communities that provide short term and long term residential care and other services for residents; managed senior living communities that provide short term and long term residential care and other services for residents; properties leased to medical providers, medical related businesses, clinics and biotech laboratory tenants (MOBs), and all other, including certain properties that offer wellness, fitness and spa services to members.",0.01314549334347248,0.007294903974980116,0.9795596599578857,neutral,0.005850589368492365
7,2018-11-18 07:00:00,"Properties in triple net senior living communities segment include leased independent living communities, assisted living communities and skilled nursing facilities.",0.014350221492350101,0.006974975578486919,0.9786747694015503,neutral,0.007375245913863182
8,2018-11-18 07:00:00,Properties in managed senior living communities segment include managed independent living communities and assisted living communities.,0.01340467482805252,0.007717893458902836,0.9788774847984314,neutral,0.005686781369149685
9,2018-11-18 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
10,2018-11-18 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
11,2018-11-18 07:00:00,"EPS GROWTH RATE IN THE IMMEDIATE PAST AND FUTURE: LOOK AT THE TOTAL DEBT/EQUITY:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

CELGENE CORPORATION ( CELG ) is a large-cap value stock in the Biotechnology & Drugs industry.",0.05348915234208107,0.005366003140807152,0.9411447644233704,neutral,0.04812315106391907
12,2018-11-18 07:00:00,The rating according to our strategy based on David Dreman is 64% based on the firm's underlying fundamentals and the stock's valuation.,0.024931136518716812,0.005442031659185886,0.969626784324646,neutral,0.0194891057908535
13,2018-11-18 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
14,2018-11-18 07:00:00,Company Description: Celgene Corporation is an integrated global biopharmaceutical company.,0.06903363019227982,0.005242857616394758,0.9257234930992126,neutral,0.06379077583551407
15,2018-11-18 07:00:00,"The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.",0.06457137316465378,0.004339935723692179,0.9310886859893799,neutral,0.06023143604397774
16,2018-11-18 07:00:00,"Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide).",0.03344940394163132,0.006323926150798798,0.9602266550064087,neutral,0.02712547779083252
17,2018-11-18 07:00:00,"Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology.",0.041079018265008926,0.0046246238052845,0.9542964100837708,neutral,0.036454394459724426
18,2018-11-18 07:00:00,"The Company also markets ISTODAX, which is an epigenetic modifier.",0.03922765702009201,0.0045734066516160965,0.9561989307403564,neutral,0.03465425223112106
19,2018-11-18 07:00:00,The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.,0.49385446310043335,0.01661142148077488,0.48953408002853394,positive,0.477243036031723
20,2018-11-18 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
21,2018-11-18 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
22,2018-11-18 07:00:00,"EPS GROWTH RATE IN THE IMMEDIATE PAST AND FUTURE: LOOK AT THE TOTAL DEBT/EQUITY:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BAXTER INTERNATIONAL INC ( BAX ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.3206302225589752,0.007687469013035297,0.6716822981834412,neutral,0.3129427433013916
23,2018-11-18 07:00:00,The rating according to our strategy based on David Dreman is 64% based on the firm's underlying fundamentals and the stock's valuation.,0.024931136518716812,0.005442031659185886,0.969626784324646,neutral,0.0194891057908535
24,2018-11-18 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
25,2018-11-18 07:00:00,"Company Description: Baxter International Inc., through its subsidiaries, provides renal and hospital products.",0.016776859760284424,0.00666993809863925,0.9765532612800598,neutral,0.010106921195983887
26,2018-11-18 07:00:00,The Company operates through two segments: Hospital Products and Renal.,0.015520949847996235,0.00666307145729661,0.9778159856796265,neutral,0.008857877925038338
27,2018-11-18 07:00:00,"Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.",0.023244887590408325,0.005879237316548824,0.9708758592605591,neutral,0.017365649342536926
28,2018-11-18 07:00:00,"The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis ( HD ), continuous renal replacement therapy (CRRT) and additional dialysis services.",0.13980115950107574,0.004776298999786377,0.8554225564002991,neutral,0.13502486050128937
29,2018-11-18 07:00:00,"Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.",0.01395258679986,0.007541074883192778,0.9785063862800598,neutral,0.006411511916667223
30,2018-11-18 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
31,2018-11-18 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
32,2018-11-18 07:00:00,"EPS GROWTH RATE IN THE IMMEDIATE PAST AND FUTURE: LOOK AT THE TOTAL DEBT/EQUITY:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

GLAXOSMITHKLINE PLC (ADR) ( GSK ) is a large-cap growth stock in the Major Drugs industry.",0.31929633021354675,0.007692126557230949,0.6730115413665771,neutral,0.31160420179367065
33,2018-11-18 07:00:00,The rating according to our strategy based on David Dreman is 64% based on the firm's underlying fundamentals and the stock's valuation.,0.024931136518716812,0.005442031659185886,0.969626784324646,neutral,0.0194891057908535
34,2018-11-18 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
35,2018-11-18 07:00:00,Company Description: GlaxoSmithKline plc is a global healthcare company.,0.04741472750902176,0.004762168973684311,0.9478231072425842,neutral,0.04265255853533745
36,2018-11-18 07:00:00,"The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare.",0.017749639227986336,0.005729556083679199,0.976520836353302,neutral,0.012020083144307137
37,2018-11-18 07:00:00,"The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.",0.021321987733244896,0.005697332788258791,0.9729806184768677,neutral,0.015624655410647392
38,2018-11-18 07:00:00,"The Company makes a range of prescription medicines, vaccines and consumer healthcare products.",0.024385910481214523,0.004767822567373514,0.9708462953567505,neutral,0.019618088379502296
39,2018-11-18 07:00:00,"The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases.",0.047144655138254166,0.0041726212948560715,0.9486826658248901,neutral,0.04297203570604324
40,2018-11-18 07:00:00,The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people.,0.03957914561033249,0.005050712265074253,0.9553700685501099,neutral,0.03452843427658081
41,2018-11-18 07:00:00,"The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories.",0.03317825123667717,0.0044503165408968925,0.9623714685440063,neutral,0.028727933764457703
42,2018-11-18 07:00:00,"Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem.",0.023405276238918304,0.004747398663312197,0.9718472957611084,neutral,0.018657878041267395
43,2018-11-18 07:00:00,"Its brands include Panadol, abreva, polident and physiogel.",0.02747415378689766,0.0054054162465035915,0.9671204090118408,neutral,0.02206873707473278
44,2018-11-18 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
45,2018-11-18 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
46,2018-11-18 07:00:00,"EPS GROWTH RATE IN THE IMMEDIATE PAST AND FUTURE: LOOK AT THE TOTAL DEBT/EQUITY:

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on David Dreman has returned 100.37% vs. 173.51% for the S&P 500.",0.7095971703529358,0.22195583581924438,0.06844696402549744,positive,0.4876413345336914
47,2018-11-18 07:00:00,"For more details on this strategy, click here

About David Dreman : Dreman's Kemper-Dreman High Return Fund was one of the best-performing mutual funds ever, ranking as the best of 255 funds in its peer groups from 1988 to 1998, according to Lipper Analytical Services.",0.9232067465782166,0.017307868227362633,0.059485431760549545,positive,0.9058988690376282
48,2018-11-18 07:00:00,"At the time Dreman published Contrarian Investment Strategies: The Next Generation, the fund had been ranked number one in more time periods than any of the 3,175 funds in Lipper's database.",0.29015251994132996,0.02072846330702305,0.6891190409660339,neutral,0.26942405104637146
49,2018-11-18 07:00:00,"In addition to managing money, Dreman is also a longtime Forbes magazine columnist.",0.041284967213869095,0.010875360108911991,0.9478397369384766,neutral,0.03040960803627968
50,2018-11-18 07:00:00,About Validea : Validea is an investment research service that follows the published strategies of investment legends.,0.01593991555273533,0.006665502674877644,0.9773945808410645,neutral,0.009274412877857685
51,2018-11-18 07:00:00,"Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.",0.08751807361841202,0.01020655408501625,0.9022754430770874,neutral,0.07731151580810547
52,2018-11-18 07:00:00,"For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.009221812710165977,0.018771812319755554,0.9720063209533691,neutral,-0.009549999609589577
